Chemotherapy for the treatment of patients with metastatic colorectal cancer: An overview

World Journal of Surgery

Volumn 21, Issue 7, 1997, Pages 748-762

  Isacoff, William H ^a   Borud, Katrina ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLOXURIDINE; FLOXURIDINE PHOSPHATE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FLUOROURIDINE TRIPHOSPHATE; FOLINIC ACID; IRINOTECAN; RALTITREXED; THYMIDINE DIPHOSPHATE; THYMIDINE PHOSPHATE; THYMIDINE TRIPHOSPHATE; TRIMETREXATE;

CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; HUMAN; METASTASIS; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; FLOXURIDINE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; QUINAZOLINES; THIOPHENES; THYMIDYLATE SYNTHASE; TRIMETREXATE;

EID: 0030847561     PISSN: 03642313     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002689900301     Document Type: Review

References (161)

1. Parker, S.L., Tang, T., Bolden, S., Wingo, P.A.: Cancer Statistics, 1996. CA Cancer J. Clin. 46:5-9, 1996
2. Cohen, A.M., Shank, B., Friedman: Colorectal cancer. In Cancer: Principles and Practice of Oncology. T. De Vita Jr., S. Hellman, S. Rosenberg, editors. Philadelphia, Lippincott, 1989, pp. 2275-2298
3. Kemeny, M.M., Busch, E.: Colorectal cancer: hepatic-directed therapy - the role of surgery, regional chemotherapy and novel modalities. Semin. Oncol. 22:494, 1995
4. Heidelberger, C., Chauchuri, N.K., Danenberg, P., et al.: Fluorinated pyrimidincs: a new class of tumor inhibitory compounds. Nature 179:663, 1957
5. Carter, S.K.: Large bowel cancer: the current status of treatment. J. Natl. Cancer Inst. 56:3, 1976
6. Moertel, C.G., Reitemeyer, R.J.: Advanced Gastrointestinal Cancer: Clinical Management and Chemotherapy. New York, Harper & Row, 1969
7. Kemeny, N.: Chemotherapy for colorectal carcinoma: one small step forward, one step backward. J. Clin. Oncol. 13:1287, 1995
8. Curreri, A.R., Ansfield, F.J., McIver, T.A., Weisman, H.A., Heidelberger, C.: Clinical studies with 5-fluorouracil. Cancer Res. 18:418, 1958
9. Ansfield, R., Klotz, J., Nealon, T., Ansfield, R., Klotz, J., Nealon, T., Rainirez, G., Minton, J., Hill, G., Wilson, W., Davis, H., Cornell, G.: A phase III study comparing the clinical utility of four regimens of 5-fluorouracil. Cancer 39:34, 1977
10. Moertel, C.G., Reitemeyer, R.J.A., Moertel, C.G., Reitemeier, R.J., Hahn, R.G.: Therapy with the fluorinated pyrimidines. In Advanced Gastrointestinal Cancer, C.G. Moertel, R.J. Reitemeier, editors. New York, Hoeber-Harper, 1969, pp. 86-107
11. Grem, J.L.: 5-Fluorouracil plus leucovorin in cancer therapy. In Principles and Practice of Oncology (2nd ed., vol. 2), V.T. De Vita Jr., S. Hellman, S.A. Rosenberg, editors. Philadelphia, Lippincott, 1988, pp. 1-13
12. Heidelberger, C., Danenberg, P.V., Moran, R.G.: Fluorinated pyrimidines and their nucleosides. In: Advances in Enzymology and Related Areas in Molecular Biology, A. Meiste, editor, New York, John Wiley and Sons, 1983, pp. 57-119
13. Grem, J.L., Hoth, D.F., Hamilton, J.M.: Overview of the current status and future direction of clinical trials with 5-fluorouracil in combination with folinic acid. Cancer Treat. Rep. 77:1249, 1987
14. Armstrong, R.D.: Fluoropyrimidine activity and resistance at the cellular level. In Resistance to Antineoplastic Drugs, D. Kessel, editor. Boca Raton, FL, CRC Press, 1989, pp. 317-351
15. Danenberg, P.V., Danenberg, K.D.: Effect of 5′10-methylenetetrahydrofolate on the dissociation of 5-fluoro-2-deoxyuridylate from thymidylate synthetase: evidence for an ordered mechanism. Biochemistry 17:4018, 1978
16. Ullman, B., Lee, M., Martin, D.W., Ullman, B., Lee, M., Martin, D.W., Santi, D.U.: Cytotoxicity of 5-flouro-2-dcoxyuridine: requirement for reduced folate cofactors and antagonism by methotrexate. Proc. Natl. Acad. Sci. U.S.A. 75:980, 1978
17. Houghton, J.A., Maroda, S.J., Phillips, J.O., Houghton, P.J.: Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinoma in mice. Cancer Res. 41:144, 1981
18. MacMillan, W.E., Winberg, W.H., Welling, P.G.: Pharmacokinetics of 5-fluorouracil in humans. Cancer Res. 38:3479, 1978
19. Drewinko, B., Yang, L.Y.: Cellular basis for the inefficiency of 5-fluorouracil in human colon carcinoma. Cancer Treat. Rep. 69: 1391, 1985
20. Keyomarsi, K., Moran, R.G.: Mechanisms of the cytotoxic synergism of fluoropyrimidines and folinic acid in mouse Ieukemic cells. Biol. Chem. 263:14402, 1988
21. Aschele, C., Sobreto, A., Fuderan, M.A., Bertino, J.R.: Novel mechanisms of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res. 52:1855, 1992
22. Evans, R.M., Laskin, J.D., Hakala, M.T.: Assessment of growth limiting events caused by 5-fluorouracil in mouse cells and human cells. Cancer Res. 40:4113, 1980
23. Izzo, J., Fandi, A., Villalobos, W., Azli, N., Bachouchi, M., Levin, F.M., Benahmed, M., Arinaud, J.P., Rougier, P., Cvitkovic, E.: Low-dose protracted 5-fluorouracil infusion in solid tumors. J Infus. Chemother. 4:135, 1954
24. Conti, J.A., Kemeny, N.E., Saltz, L.B., McKenzie, A.A., Grossano, D.D., Bertino, J.R. Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen in advanced colorectal cancer. Cancer 25:769, 1995
25. Shah, A., MacDonald, W., Goldie, J., Gudauskas, G., Brisehois, B.: 5-FU infusion in advanced colon cancer: a comparison of three dose schedules. Cancer Treat. Rep. 69:7, 1985
26. Seifert, P., Baker, L., Reed, M.L., Vatitkevicius, V.K.: Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 36:123, 1975
27. Hartman, H.A., Kessinger, A., Lemon, H.M., Foley, J.F.: Five day continuous infusion of 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 36:123, 1975
28. Lokich, J., Bothe, A., Fine, N., Perri, J.: Phase I study of protracted infusion of 5-fluorouracil. Cancer 48:2565, 1981
29. Leichman, L., Leichman, C.G., Kinzie, J., Weaver, D., Evans, L.: Long term low dose 5-fluorouracil in advanced measurable colon cancer: no correlation between toxicity and efficacy. Proc. Am. Soc. Clin. Oncol. 4:86, 1985 (abstr)
30. Belt, R.I., Davidven, M.L., Myron, M.C., Barrett, S.: Continuous low dose 5-fluorouracil for adenocarcinoma: confirmation of activity. Proc. Am. Soc. Clin. Oncol. 4:90, 1985 (abstr)
31. Hansen, R., Quebbeman, E., Ausman, R., Frick, J., Ritch, P., Schulte, W., Haas, C., Beatty, P., Anderson, T.: Continuous systemic 5-fluorouracil infusion in advanced colorectal cancer: results in 91 patients. J. Surg. Oncol. 7:94, 1988 (abstr)
32. Kuo, S., Finck, S., Cho, J., Glenn, D., Wong, S., Billups, T., Slater, L., Cohen, A., Armentrout, S.: Continuous ambulatory infusional 5-fluorouracil chemotherapy in advanced colorectal cancer: a single institutional retrospective study. Proc. Am. Soc. Clin. Oncol. 8:126, 1989 (abstr)
33. Molina, R., Fabian, C., Slavik, M., Dahlberg, S.: Reversal of palmar plantar erythrodysesthesia by B6 without loss of response in colon cancer patients receiving 200 mg/m/d continuous infusion 5-FU. Proc. Am. Soc. Clin. Oncol. 6:74, 1987 (abstr)
34. Wade, J.L., Herbst, S., Greenberg, A.: Prolonged venous infusion of 5-fluorouracil for metastatic cancer: a followup report. Proc. Am. Soc. Clin. Oncol. 7:94, 1988 (abstr)
35. Lokich, J.J., Ahlgren, J.D., Gullo, J.J., Philips, J.A., Fryer, J.G.: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J. Clin. Oncol. 7:425, 1989
36. Weinerman, B., Stfah, A., Fields, A., Kerr, I., Cripps, C., Shepherd, F., Wierzbicki, R., Temple, W., Maroun, J., Bogues, W., Pater, J.: A randomized trial of continuous systemic infusion (SI) versus bolus therapy (B) with 5-fluorouracil (5-FU) in metastatic measurable colorectal cancer (MCC). Proc. Am. Soc. Clin. Oncol. 9:102, 1990 (abstr)
37. Rougler, P., Paillot, B., Laplanche, A., Morvan, F., Benhamed M., Seitj, J.F., Laplaige, P., Jacob, J., Grandjouau, S., Pinon, G.N.: End results of a multicentric randomized trial comparing 5-FU in continuous infusion systemic infusion (CI) to bolus administration (B) in measurable metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 11:163, 1992 (abstr)
38. Hansen, R., Ryan, L., Anderson, T., Quebbeman, E., Haller, D.: A phase III trial of bolus 5-FU versus protracted infusion 5-FU +/-cisplatin in metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 11:171, 1992 (abstr)
39. Leichman, C.G., Fleming, T.R., Muggia, F.M., Tangen, C.M., Ardalan, B., Doroshow, J.H., Meyers, F.J., Holcombe, R.F., Weiss, G.R., Mangalik, A., Macdonald, J.S.: Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J. Clin. Oncol. 3:1303, 1995
40. Hrushesky, W.J.M., editor: Circadian Cancer Therapy. Boca Raton FL, CRC Press, 1994, pp. 241-263
41. Petit, E., Milanci, G., Levi, F., Thyss, A., Bailleul, F., Schneider, M.: Circadian varying plasma concentration of 5-fluorouracil during 5-day continuous venous infusion at constant rate in cancer patients. Cancer Res. 45:1676, 1988
42. Harris, B., Song, R., Soong, S., Diasio, R.B.: Relationship between dihydropyrimidine dehydrogenasc activity and plasma 5-fluorouracil levels: evidence for circadian variation of plasma drug levels in patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res. 56:197, 1990
43. Harris, B.E., Song., R., He, Y.J., Soong, S.J., DiAsio, R.B.: Circadian rhythm of rat liver dihydropyrimidine dehydrogenase. Biochem. Pharmacol. 37:41, 1588
44. Nagnib, F.M., Soong, S.J., Louni, M.H.: Circadian rhythm of orotate phosphoribosyl transferase, pyrimidine nucleoside phosphorylase and dihydrouracil dehydrogenase in mouse liver. Biochem. Pharmacol. 45:667, 1993
45. Levi, F., Soussain, A., Adam, R., Caussanel, J., Metzger, G., Misset, J.L.: Programmable-in-time pumps for chromotherapy of patients with colorectal cancer with 5-day circadian-modulated venous infusion of 5-fluorouracil. Proc. Am. Soc. Clin. Oncol. 8:429, 1989 (abstr)
46. Bjarnason, G.A., Kerr, I.G., Doyle, N., Macdonald, M., Sone, M.: Phase I study of 5-fluorouracil and leucovorin by a 14-day circadian infusion in metastatic adenocarcinoma patients. Cancer Chemother. Pharmacol. 33:221, 1993
47. Levi, F., Misset, J.L., Brienza, S., Adam, R., Metzger, G., Itzakhi, M., Caussanel, J.P., Kunstlinger, F., Lecouturier, S., Descorps-Declere, A., Jasmin, C., Bismuth, H., Reinberg, A.: A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using an ambulatory multichannel programmable pump. Cancer 69:893, 1992
48. Allegra, C.J.: Biochemical modulation: a modality that has come of therapeutic age. J. Clin. Oncol. 9:1723, 1991
49. Sotos, G.A., Grogan, L., Allegra, C.J.: Preclinical and clinical aspects of biomodulation of 5-fluorouracil. Cancer Treat. Rev. 20:11, 1994
50. Grem, J.: 5-Fluoropyrimidines. In Cancer Chemotherapy and Biotherapy, Principles and Practice (2nd ed.), B.A. Chabner, D.L. Longo, editors. Philadelphia, Lippincott-Raven, 1996, pp. 140-211
51. Madajewicz, S., Petrelli, N., Rustwn, Y., Carnnbell, J., Herrera, L., Mittelman, A., Perry, A., Creaven, P.: Phase I-II trial of high dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer. Cancer Res. 44:4667, 1984
52. Machover, D., Goldschmidt, E., Chollet, P., Metzger, G., Zittoun, J. Marquet, J., Vandenbulcke, J-M., Misset, J-L., Schwarzenberg, L., Fourtillan, J.B., Gaget, H., Mathd, G.: Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high dose folinic acid. J. Clin. Oncol. 4:685, 1986
53. Bruckner, H., Ruboz, J., Spiegelman, M.: An efficient leucovorin and 5-fluorouracil sequence: dose escalation and pharmacological monitoring. Proc A.A.C.R. 24:547, 1983 (abstr)
54. Zakem, M., Hines, J.D., Adelstein, D.J., Rustiun, Y.M.: High-dose leucovorin and 5-fluorouracil in refractory and relapsed colorectal carcinoma. Proc. Am. Soc. Clin. Oncol. 5:81, 1986 (abstr)
55. Bruckner, H., Ruboz, T., Spiegehnan, M., Ambinder, E., Hart, R., Holland, J.F.: Therapeutic efficacy of the combination of 5-fluorouracil and high-dose leucovorin in patients with advanced colorectal carcinoma: single daily intravenous dose for five days. In The Current Status of 5-Fluorouracil Leucovorin Combination, H.W. Bruckner, Y.N. Rusturn, editors. New York, Park Row Publishers, 1984
56. Budd, G.T., Fleming, T.R., Bukowski, R.M., MeCracken, J.D., Rivkin, S.E., O'Bryan, R.M., Balcerzak, S.P., Macdonald, J.S.: 5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: a randomized comparison: a Southwest Oncoloey Group study. J. Clin. Oncol. 5:272, 1987
57. Bertrand, M., Doroshow, J.H., Multhauf, P., Blayney, D.W., Carr, B.I., Cecchi, G., Goldberg, D., Leong, L., Margolin, K., Metter, G., Staples, R.: High-dose continuous infusion folinic acid and bolus 5-fluorouracil in patients with advanced colorectal cancer: a phase II study. J. Clin. Oncol. 4:1058, 1986
58. Cunningham, J., Bukowski, R.M., Budd, G.T., Weick, J.K., Purvis, J.: 5-Fluorouracil and folinic acid: a phase I-II trial in gastrointestinal malignancy. Invest. New Drugs 2:291, 1984
59. Green, H., Desai, A., Levick, S., Tester, W.: Combined 5-fluorouracil infusion and high-dose folinic acid in the treatment of metastatic gastrointestinal cancer. Proc. Am. Soc. Clin. Oncol. 5:89, 1986
60. Erlichman, C., Fine, S., Wong, A., Elhakin, T.: A randomized trial of fluorouracil and folic acid in patients with metastatic colorectal carcinoma. J. Clin. Oncol. 6:469, 1988
61. Petrelli, N., Douglass, H.O., Herrera, L., Russell, D., Stablein, D.M., Bruckner, H.W., Mayer, R.J., Schinella, R., Green, M.D., Muggia, F.M., Megibow, A., Greenwald, E.S., Bukowski, R.M., Harris, J., Levin, B., Gaynor, E., Loutri, A., Kalser, M.H., Barkin, J.S., Benedetto, P., Woolley, P.V., Nauta, R., Weaver, D.W., Leichman, L.P. (Gastrointestinal Tumor Study Group): The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J. Clin. Oncol. 7:1419, 1989
62. Poon, M.A., O'Connell, M.J., Moertel, C.G., Wieand, H.S., Cullinau, S.A., Everson, L.K., Krook, J.E., Mailliard, J.A., Laurie, J.A., Tschetter, L.K., Wiesenfield, M.: Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J. Clin. Oncol. 7:1407, 1989
63. Piedbois, P., Buyse, M., Rustum, Y., Machover, D., Erlichman, C., Carlson, R.W., Valone, F., Labianca, R., Doroshow, J.H., Petrelli, N.: Modulation of fluorouracil by leucovorin in advanced colorectal cancer. J. Clin. Oncol. 10:896, 1992
64. Petrelli, N., Herrera, L., Rustum, Y., Burke, P., Creaven, P., Stulc, J., Enuich, L.J., Mitte, A.: A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colordctal carcinoma. J. Clin. Oncol. 5:1559, 1987
65. Valone, F.H., Friedman, M.A., Wittlinger, P.S., Drakes, T., Eisenberg, P.D., Malec, M., Hannigan, J.F., Brown, B.W.: Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil or sequential methotrexate, fluorouracil and leucovorin: a randomized trial of the Northern California Oncology Group. J. Clin. Oncol. 7:1427, 1989
66. Doroshow, J.H., Mulhart, P., Leong, L., Margolin, K., Litchfield, T., Akrnan, S., Carr, B., Mertraud, M., Goldberg, D., Blayney, D., Odujinrin, O., DeLap, R., Shuoter, J., Newman, E.: Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J. Clin. Oncol. 8:491, 1990
67. Nobile, M.T., Rosso, R., Sertoli, M.R., Rubagotti, A., Vidili, M.G., Guglielmi, A., Venturini. M., Canobbio, L., Fassio, T., Gallo, L., Galligioni, E., Gallotti, P., Bruzzi, P., Sobrero, A.: Randomized comparison of weekly bolus 5-fluorouracil with or without leucovorin in metastatic colorectal carcinoma. Eur. J. Cancer 28A:1823, 1992
68. Leichman, C.G., Leichman, L., Spears, C.P., Rosen, P.J., Jeffers, S., Groshen, S.: Prolonged continuous infusion of fluorouracil with weekly bolus leucovorin: a phase II study in patients with disseminated colorectal cancer. J. Natl. Cancer Inst. 85:41, 1993
69. Tempero, M., Berg, A., Block, M., Hutchins, M., Moravec, D., Langdon, R.: A phase II trial of protracted therapy with 5-fluorouracil and daily leucovorin in metastatic colorectal cancer. J. Infus. Chemother. 4:112, 1994
70. Bertino, J.R., Mini, E., Fernandez, DJ.: Sequential methotrexate and 5-fluorouracil: mechanisms of synergy. Semin. Oncol. 10(2):2, 1983
71. Bertino, J.R., Sawicki, W.L., Lindqudst, C.A., Gupta, V.S.: Scheduledependent antitumor effects of methotrexate and 5 fluorouracil. Cancer Res. 37:327, 1977
72. Isacoff, W.H., Nagel, G., Heunnekens, F.M., Wihnanns, W., Cadman, E., Cano, J.P., Diehl, V., Bertino, J.R.: Methotrexate Symposium: Proceedings of the 11th International Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, American Society for Microbiology, 1979, pp. 1475-1484
73. Bektino, J.R.: Ode to methotrexate. J. Clin. Oncol. 11:5, 1993
74. Allegra, C.J., Chabner, B.A., Drake, J.C., Lutz, R., Rodbard, D., Jolivet, J.: Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. Biol. Chem. 260:9720, 1985
75. Jacobs, S.A., Adwnson, R.H., Chabner, B.A., Deff, C.J., Johns, D.G.: Stoichiometric inhibition of mammalian dihydrofolate reductase by the α-glytaniyl metabolite of methotrcxatc 4-amino-4-deoxy-M-10-methyl-pteroyl-glutamyl-α-glutamate. Biochem. Biophys. Res. Commun. 634:692, 1975
76. Cadman, E.D., Heimer, R., Davis, L.: Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: explanation for drug synergism. Science 205:1135, 1979
77. Bruckner, H.W., C.H.: MTX/5-FU trials in gastrointestinal and other cancers. Semin. Oncol. 10(2):32, 1983
78. Isacoff, W.H., Tisman, G., Block, J.B.: Treatment of advanced colorectal carcinoma with high-dose methotrexate given alone and in combination with 5-fluorouracil. Proc. A.A.C.R. 20:381, 1979
79. Nordic Gastrointestinal Tumor Adjuvant Therapy Group: Superiority of sequential methotrexate, fluorouracil, and leucovorin to fluorouracil alone in advanced symptomatic eolorectal carcinoma: a randomized trial. J. Clin. Oncol. 7:14, 1989
80. Marsh, J.C., Bertino, J.P., Katz, K.H., Davis, C.A., Durivage, H.J., Rome, L.S., Richards, F., Capizzi, R.L., Farber, L.R., Pasquale, D.N., Stuart, R., Koletsky, A.J., Makuch, R., O'Hollaren, K.: The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer. J. Clin. Oncol. 99:371, 1991
81. Glimelius, B., Gimnau, C., Graffinan, S., Pahlrnan, L., Stahle, E.: 1. Sequential methotrexate-5-FU-leucovorin (MVL) in advanced colorectal cancer. Eur. J. Cancer Oncol. 22:295, 1986
82. Poon, M.A., O'Connell, M.J., Wieand, H.S., Krook, J.E., Gerstner, J.B., Tschetter, L.K., Levitt, R., Kardinal, C.G., Mailliard, J.A.: Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J. Clin. Oncol. 9:1967, 1991
83. Piedbois, P., Buyse, M., Blijham, G., Glimelius, B., Herrmann, R., Valone, F., Carlson, R., Machiavelli, M., Delfino, C., Abad, A., Petrelli, N.: Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J. Clin. Oncol. 12:960, 1994
84. Elias, L., Crissman, H.A.: Interferon effect upon the adenocarcinoma 38 and HL-60 cell lines: antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites. Cancer Res. 48:4868, 1988
85. Elias, L., Sandoval, J.M.: Interferon effects upon fuorouracil metabolism by HL-60 cells. Biochem. Biophys. Res. Commun. 163:867, 1989
86. Chu, E., Zinn, S., Boarman, D., Allegra, C.J.: Interaction of α-interferon and 5-fluorouracil in H630 human colon carcinoma cell line. Cancer Res. 50:58340, 1990
87. Grem, J.L., Chu, E., Boarman, D., Balls, F., Murphy, R.F., McAtee, N., Allegra, C.J.: Biochemical modulation of fluorouracil with leucovorin and interferon: preclinical and clinical investigations. Semin. Oncol. 19:366, 1992
88. Wadler, S., Lembersky, B., Atkins, M., Kirkwood, J., Petrelli, N.: Phase II trial of fluorouracil and recombinant interferon alpha-Za in patients with advanced colorectal carcinoma: an Eastern Cooperative Group study. J. Clin. Oncol. 9:1806, 1991
89. Wadler, S., Wiernik, P.H.: Clinical update on the role of fluorouracil and recombinant interferon alpha-za in the treatment of colorectal carcinoma. Semin. Oncol. 17(1):16, 1990
90. Pazdur, R., Ajani, J.A., Pan, Y.Z., Winn, R., Jackson, D., Shepard, B., DuBrow, R., Campos, L., Quaraishi, M., Faintuch, J., Abbruzzese, J.L., Gutterman, J., Levin, B.: Phase II study of fluorouracil and recombinant interferon alpha-Za in previously untreated advanced colorectal carcinoma. J. Clin. Oncol. 12:2027, 1990
91. Diaz-Rubio, E., Jimeno, J., Camps, C., Aranda, E., Massuti, B., Blanco, E., Anton, A., Lizon, J., Gonzalez-Larriba, J.L.: Treatment of advanced cold rectal cancer with recombinant interferon alpha and fluorouracil: activity in liver metastasis. Cancer Invest. 10:259, 1992
92. Kemeny, M., Younes, A.: Alpha-2a interferon and 5-fluorouracil for advanced colorectal carcinoma: the Memorial Sloan Kettering experience. Semin. Oncol. 19:171, 1992
93. Grem, J.L., McAtee, N., Murphy, R.F., Balis, F.M., Steinberg, S.M., Hamilton, J.M., Sorensen, J.M., Sartor, O., Kramer, B.S., Goldstein, L.J., Gay, L.M., Caubo, K.M., Goldspiel, B.G., Allegra, C.J.: A pilot study of interferon alpha-2a in combination with fluorouracil plus high dose leucovorin in metastatic gastrointestinal carcinoma. J. Clin. Oncol. 9:1811, 1991
94. Raderer, M., Scheithauer, W.: Treatment of advanced colorectal cancer with 5-fluorouracil and Interferon alpha: an overview of clinical trials. Eur. J. Cancer 316:1002, 1995
95. Collins, K.D., Stark, G.R.: Aspartate transcarbamylase interaction with the transition state analogue N-(phosphoacetyl)-L-aspartate. J. Biol. Chem. 246:6599, 1971
96. Spiegehnan, S., Sawyer, R., Nayak, R., Ritzi, E., Stolfi, R., Martin, D.: Improving the antitumor activity of 5-fluorouracil by increasing its incorporation into RNA via metabolic modulation. Proc. Natl. Acad. Sci. U.S.A. 77:4966, 1980
97. Martin, D.S., Stolfi, R.L., Saywer, R.C., Spiegehnan, S., Casper, E.S., Young, C.W.: Therapeutic utility of utilizing low doses of N-(phosphoacetyl)-L-aspartic acid in combination with 5-fluorouracil: a murine study with clinical relevance. Cancer Res. 43:2317, 1983
98. Ardelan, B., Singh, G., Silberman, H.: A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphoacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers. J. Clin. Oncol. 6:1053, 1988
99. O'Dwyer, P.J., Paul, A.R., Walczak, J., Weiner, L.M., Litwin, S., Comis, R.L.: Phase II study of biochemical modulation of 5-fluorouracil by low-dose PALA in patients with colorectal cancer. J. Clin. Oncol. 8:1497, 1990
100. Kemeny, N., Conti, J.A., Seiter, K., Niedzwiecki, D., Botet, J., Martin, D., Costa, P., Wiseberg, J., McCulloch, W.: Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer. J. Clin. Oncol. 10:747, 1992
101. Spears, C.P., Gustavsson, B.G., Berne, Frosing, R., Bernstein, L., Hayes, A.A.: Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil. Cancer Res. 45:5894, 1988
102. Horikoshi, T., Danenberg, K.D., Stadlbauer, T.H., Volkenandt, M., Shea, L.C., Aigner, K., Gustawson, B., Leichman, L., Frosing, R., Ray, M.: Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorasc gene expression in human tumors using polymerase chain reaction. Cancer Res. 52:108, 1992
103. Johnston, P.G., Lenz, H.J., Leichman, C.G., Danenberg, K.D., Allegra, C.J., Danenberg, P.V., Leichman, L.: Thymidylate gene and protein expression correlate associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 55:1407, 1995
104. Alexander, H.R., Grem, J.L., Hamilton, J.M., Pass, H.I., Hong, M., Fraker, D.L., Steinberg, M., McAtt, N., Allegra, C.J., Johnston, P.G.: Thymidylate synthase protein expression: association with response to neoadjuvant chemotherapy and resection for locally advanced gastric and gastroesophageal adenocarcinoma. Cancer J. 1:49, 1995
105. Lenz, H.J., Leichman, C.G., Danenberg, K.D., Danenberg, P.V., Groshen, S., Cohen, H., Laine, L., Crookes, P., Silverman, H., Baranda, J., Garcia, Y., Li, J., Leichman, L.: Thymidylate synthase MRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J. Clin. Oncol. 14:176, 1995
106. Swain, S.M., Lippman, M.E., Egan, E.F., Drake, J.C., Steinberg, S.M., Allegra, C.J.: Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J. Clin. Oncol. 7:890, 1989
107. Chu, E., Koeller, D.M., Johnston, P.G., Zinn, S., Allegra, C.J.: Regulation of thymidylate synthase in human colon cells treated with 5-fluorouracil and interferon-gamma. Mol. Pharmacol. 43:527, 1993
108. Jackman, A.L., Taylor, G.A., Gibson, W., Kiinbell, R., Brown, M., Calvert, A.H., Judson, I.R., Hughes, L.R.: ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res. 51:5579, 1991
109. Pazdur, R.: New agents in the treatment of colorectal cancer: tomudex, UFT and doxifluridine. Cancer Invest. 12:18, 1995 (abstr)
110. Zaleberg, J.: ZD1694 A new thymidylate synthase inhibitor: results in the treatment of colorectal carcinoma. Cancer Invest. 12:43, 1994 (abstr)
111. Cunningham, D., Zaleberg, J., Francoise van Cutsem, E., Schornagel, J.H., Adenis, A., Green, M., Starkhammer, H., Hanrahan, A., Ellis, P., Azab, M.: Tolmudex (ZD1694) a new thymidylate synthase inhibitor with good antitumor activity in advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol. 13:199, 1994 (abstr)
112. Seitz, J.E., Cunningham, D., Roth, U., Oliver, I.N., vanCutsem, E., Keff, D., Svensson, C., Ferez Manga, G., Harper, P., Zalcberg, J., Lowery, K., Azab, M.: Final results and survival data of a large randomized trial of tomudex in advanced colorectal cancer (ACC) confirm comparable efficacy to 5-fluorouracil plus leucovorin (5FU + IV). Proc. Am. Soc. Clin. Oncol. 15:201, 1966 (abstr)
113. Elslager, E.F., Johnson, J.L., Werbel, L.M.: Folate antagonists 20 synthesis and antitumor and antimalarial properties of trimetrexate and related 6-[(phenylaminal)methyl]-2,4-quinazolinediamines. J. Med. Chem. 26:1753, 1983
114. O'Dwyer, P., DeLap, R., Kings, S.A., Grillo-Lopez, A.J.: Trimetrexate: clinical development of a nonclassical antifolate. Natl. Cancer Inst. Monogr. 5:105, 1987
115. Karnan, B., Cashmore, A., Dreyer, R., Eibi, B., Bertino, J.R.: 1. Update and efficacy of trimetrexate, a nonclassical antifolate in methotrexate resistant leukemia cells in vitro. Biochem. Pharmacol. 33:1697, 1984
116. Bertino, J.R.: Toward improved selectivity in cancer chemotherapy: the Richard and Hinda Rosenthal award lecture. Cancer Res. 39:293, 1979
117. Romanini, A., Li, W.W., Coloflore, J.R., Bertino, J.R.: 1. Leucovorin enhances cytotoxicity of trimetrexate/fluorouracil, but not methotrexate/fluorouracil in CCRF-CEM cells. J. Natl. Cancer Inst. 84: 1033, 1992
118. Jackson, R.C., Leopold, W.R., Hamelehle, K.L., Fry, D.W.: Preclinical studies with trimetrexate: a review of conclusions and unanswered questions. Semin. Oncol. 15(2):1, 1988
119. Stewart, J.A.: Safety and tolerance of trimetrexate: results of a phase II multicenter study in patients with metastatic cancer refractory to conventional therapy or for which no conventional therapy exists. Semin. Oncol. 15(2):10, 1988
120. Leopold, W.R., Dykes, D.J., Griswold, D.P.: Therapeutic synergy of trimetrexate (CI-898) in combination with doxorubicin, vincristine, Cytoxan, thioguanine, cisplatin or 5-fluorouracil against intraperitoneally implanted P388 leukemia. Natl. Cancer Inst. Monogr. 5:99, 1987
121. Hudes, G.R., Comis, R.L.: Phase 1 and 2 studies of trimetrexate administered in combination with fluorouracil in patients with metastatic cancer. Semin. Oncol. 15(2):41, 1988
122. Danhauser, L.L., Heimer, R., Cadman, E.: Lack of enhanced cytotoxicity of cultured L1210 cells using folinic acid in combination with sequential methotrexate and fluorouracil. Cancer Chemother. Pharmacol. 15:2149, 1985
123. Conti, J.A., Kemeny, N., Seiter, K., Goker, E., Tong, W., Andre, M., Ragusa, K.: Trial of sequential trimetrexate, fluorouracil and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma. J. Clin. Oncol. 12:695, 1994
124. Blanke, C.O., Kasimis, B., Capizzi, R.: A pilot study of sequential trimetrexate, fluorouracil, and high-dose leucovorin in patients with advanced colorectal cancer. Cancer Invest. 14:23, 1996
125. Kuniinoto, T., Nitta, K., Tanaka, T., Uehara, N., Baba, H., Takeuchi, M., Yokokura, T., Sawada, S., Miyasaka, T., Mutai, M.: Antitumor activity of 7-ethyl-10-(4-(1-peridono)-1-piperidinol carboxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res. 47:5944, 1987
126. Wall, M.E., Wani, M.C., Cook, CE.: Plant antitumor agents: the isolation and structure of camptothecin, a novel alkaloid leukemia and tumor inhibitor from Camptotheca ocuminata. J. Am. Clin. Soc. 88:3888, 1966
127. Hsiang, Y.H., Hartzburg, R., Hecht, S., Liu, L.F.: Camptothecin induces protein-linked breaks via mammalian DNA topoisomerase. Biol. Chem. 60:14873, 1985
128. Hsiang, Y-H., Liu, L.P.: Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 48: 1722, 1988
129. Wang, J.C.: DNA topoisomerases: why so many? J. Biol. Chem. 266:6659, 1991
130. Lin, L.F.: DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 58:315, 1989
131. Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., Sato, K.: Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 57:1487, 1991
132. Shimada, Y., Yoshino, M., Wakui, A., Nakao, I., Futatsuki, K., Sakata, Y., Kambe, M., Taguchi, T., Ogawa, N.: Phase II study of CPT-11: a new camptothecin derivative in metastatic colorectal cancer. J. Clin. Oncol. 11:909, 1993
133. Rougier, P., Paillot, B., Laplanche, A., Morvan, F., Benhamed, M., Seitz, J.F., Laplaige, P., Jacob, J., Grandjouan, S., Pinon, G.N.: Multicentric phase study of first line CPT-11 (irinotecan) in advanced colorectal cancer (CRC): preliminary results. Proc. Am. Soc. Clin. Oncol. 13:200, 1994 (abstr)
134. Bugat, R., Suc, E., Rougier, P., Becouam, Y., Naieff, I., Ychou, M., Cutine, S., Extra, J.M., Adenis, A., Ganem, G.: CPT-11 (irinotecan) as second line therapy in advanced colorectal cancer (CRC): preliminary results of a multicentric phase II study. Proc. Am. Soc. Clin. Oncol. 13:200, 1994 (abstr)
135. Rothenberg, M.L., Echardt, J.R., Burns, H.A., Nelson, J., Kuhn, J.G., Chen, S.F., Hilsenbeck, S.G., Clark, G.M., Fields, S.M., Rodriguez, G.I.: Irinoteca (CPT-11) as second line therapy for patients with 5-FU refractory colorectal cancer. Proc. Am. Soc. Clin. Oncol. 13:198, 1994 (abstr)
136. Pitot, H.C., Wender, D., O'Connell, M.J., Wieand, H.S., Mailliard, J.A.: A phase II trial of CPT-11 in patients with metastatic colorectal carcinoma: a North Central Cancer Treatment Group study. Proc. Am. Soc. Clin. Oncol. 134:197, 1994 (abstr)
137. Conti, J.A., Kemeny, N.E., Saltz, L.B., Huang, Y., Tong, W.P., Chou, T.C., Sun, M., Pulliam, S., Gonzalez, C.: Irinotecan (CPT-11) is an active agent in untreated patients with metastatic colorectal cancer (CRC). Proc. Am. Soc. Clin. Oncol. 13:195, 1994 (abstr)
138. Saltz, L.B.: Irinotecan (CPT-11) in combination chemotherapy regimens. Cancer Invest. 14:38, 1996 (abstr)
139. Moertel, C.G., Schutt, A.J., Hahn, R.G., Reitemeier, R.J.: Therapy of advanced colorectal cancer with a combination of 5-fluorouracil, methyl-1,3 cis(2 chloroetbyl)-1-nitrosourea, and vincristine. J. Natl. Cancer Inst. 54:69, 1975
140. Moertel, C.G.: Chemotherapy of gastrointestinal cancer. N. Engl. J. Med. 299:1049, 1978
141. Falkson, G., Falkson, H.C.: Fluorouracil, methyl-CCNU, and vincristine in cancer of the colon. Cancer 38:1468, 1976
142. Engstrom, P., Maclntyre, J., Douglas, H., Carbone, P.: Combination chemotherapy of advanced bowel cancer. Proc. Am. Soc. Clin. Oncol. 19:384, 1978
143. Kemeny, N., Yagoda, A., Braun, D., Jr., Golbey, R.: A randomized study of two different schedules of methyl CCNC, 5-FU and vincristine for metastatic colorectal carcinoma. Cancer 43:78, 1979
144. Kemeny, N., Yagoda, A., Braun, D., Jr., Golbey, R.: Therapy for metastatic colorectal carcinoma with a combination of methylCCNU, 5-fluorouracil, vincristine, and streptozocin (MOF-strep). Cancer 45:876, 1980
145. Kemeny, N., Yagoda, A., Braun, D., Jr.: Metastatic colon carcinoma: a prospective randomized trial of methyl-CCNU, 5-fluorouracil (5-FU) and vincristine (MOF) versus MOF plus streptozocin (MOP-strep). Cancer 51:20, 1983
146. Gastrointestinal Tumor Study Group: A phase II study of methyl CCNU, vincristine, 5-fluorouracil, and streptozocin in advanced colorectal cancer. J. Clin. Oncol. 2:770, 1984
147. Lavin, P., Mittelman, A., Douglass, H., Engstrom, P., Klaassen, D.: Survival and response to chemotherapy for advanced colorectal adenocarcinoma: an Eastern Cooperative Oncology Group report. Cancer 46:1536, 1986
148. Engstrom, P.F., MacIntyre, J.M., Mittelman, A., Klaasen, DJ.: Chemotherapy of advanced colorectal carcinoma: fluorouracil alone vs two drug combinations of fluorouracil, hydroxyurea, semunole, dacarbazine, razoxane and mitomycin-C: a phase III trial by the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 7:313, 1984
149. Falkson, G., Van Eden, E.G., Falkson, H.C.: Fluorouracil, imidazole carboximide dimethyltriazine, vincristine and bis-chloroethylnitrosourea in colon cancer. Cancer 33:1207, 1974
150. Haller, D.G., Woolley, P.V., Macdonald, J.S., Smith, L.F., Schein, P.S.: Phase II trial of 5-fluorouracil, Adriamycin and mitoniycin-C in advanced colorectal cancer. Cancer Treat. Rep. 62:563, 1978
151. Buroker, T., Kim, P.N., Groppe, C., McCracken, J., O'Bryan, R., Panettiere, F., Coltman, C., Bottomley, R., Wilson, H., Bonnet, J., Thigpen, T., Vaitkevicius, V.K., Hoogstraten, B., Heilbrun, L.: 5-FU infusion with mitomycin-C vs 5-FU infusion with methyl CCNU in the treatment of advanced colon cancer. Cancer 42:1228, 1978
152. Oritz, J., Woolley, P.V.: A study of the synergistic cytotoxic effects of 5-fluorouracil and cisplatin against colon carcinoma cells using median effect analysis. Proc A.A.C.R. 12:414, 1987
153. Grem, J.L., McAtee, N., Balis, F., Murphy, R., Venzon, D., Kramer, B., Goldspiel, B., Begley, M., Allegra, C.J.: A phase II study of continuous infusion 5-flurouracil and leucovorin with weekly cisplatin in metastatic colorectal carcinoma. Cancer 72:663, 1993
154. Krizan, Z., Dimitrou, D., Suhrland, G., Arnold, D., Cook, D., Schwartz, K., Walker, W.: Six week cycles of continuous infusion (CI) 5-FU and weekly low dose cisplatin (DDP) in metastatic colorectal carcinoma. Proc. Am. Soc. Clin. Oncol. 9:103, 1190 (abstr)
155. Loehrer, P.J., Turner, S., Kubilis, P., Hui, S., Correa, J., Ansari, R., Stephens, D., Woodburn, R., Meyer, S.: A prospective randomized trial of fluorouracil versus fluorouracil plus cisplatin in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial. J. Clin. Oncol. 6:642, 1988
156. Kemeny, N., Israel, K., Niedzwiecki, D., Chapman, D., Botet, J., Minsky, B., Vinciguerra, V., Rosenbluth, R., Bosselli, B., Cochrran, C., Sheehan, K.: Randomized study of continuous infusion fluorouracil vs fluorouracil plus cisplatin in patients with metastatic colorectal cancer. J. Clin. Oncol. 8:313, 1990
157. Diaz-Rubio, E., Milla, A., Jimeno, J., Belon, J., Aranda, E., Diaz Faes, J., Crus Hernandes, J., Ayuso, M.L., Alonso, A., Anton, A., Martin, M., Gonzalez, Larriba, J.L., Sanchiz, F., Navarete, A., Masso, O.: Lack of clinical synergism between cisplatin (CDDP) and 5-fluorouracil (5-FU) in advanced colorectal cancer (CRC): results of a randomized study. Proc. Am. Soc. Clin. Oncol. 7:110, 1988 (abstr)
158. Lokich, J.J., Ahlgren, J., Cantrel, J., Heim, W.J., Wampler, G.L., Gullo, J.J., Fryer, J.G., Alt, D.E.: A prospective randomized comparison of protracted infusional 5-fluorouracil with or without weekly bolus cisplatin in metastatic colotectal carcinomas: a Mid-Atlantic Oncology Program study. Cancer 67:14, 1991
159. Diaz-Rubio, E., Zaniboni, A., Gastiaburn, J., Labianca, R., CortezFunes, H., DeBraud, F., Boni, C., Vignoud, J.: Phase II multicentric trial of oxaliplatin (L-OHP) as first line chemotherapy in metastatic colorectal carcinoma (in CRC). Proc. Am. Soc. Clin. Oncol. 15:207, 1996 (abstr)
160. Levi, F., Zidani, R., Vannetzel, J.M., Fagguiolo, R., Garufi, C., Chellet, P., Focan, C., Perpoint, B., Iacobelli, S., Le-Roi, A.: Chronomodulated vs flat infusion of 5-fluorouracil (5-FU), folinic acid (FA), and oxaliplatin (L-OHP) against metastatic colorectal cancer (MCC) in 2 consecutive European randomized multicenter trials (T). Proc. Am. Soc. Clin. Oncol. 14:204, 1995 (abstr)
161. Isacoff, W.H., Eilber, F.R., Kuchenbecker, S.L., Jacobs, A.D., Taylor, O.: Continuous infusion 5-fluorouracil given with calcium leucovorin, dipyridamole, and mitomycin-C in patients with advanced colorectal carcinoma: a phase II trial. J. Infus. Chemother. 4:107, 1994